{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.2","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Financial toxicity will be measured using the COST survey. FACIT-COST (v2) score (range: 0-44). A lower score indicates higher financial toxicity, while a higher score implies better financial well-being.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity.\n\nDaratumumab and Hyaluronidase-fihj: Given SC\n\nQuestionnaire Administration: Ancillary studies\n\nQuality-of-Life Assessment: Ancillary studies\n\nInterview: Ancillary studies","id":"OG000","title":"Treatment (daratumumab and hyaluronidase-fihj)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"At Visit 4, Day 85","title":"Financial Toxicity","type":"SECONDARY","unitOfMeasure":"scores on a scale (0-44)"}